Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Viatris Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
VTRS
Nasdaq
2834
https://www.viatris.com/en
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Viatris Inc
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
- May 6th, 2024 2:40 pm
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
- May 6th, 2024 1:50 pm
Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
- May 6th, 2024 1:16 pm
Viatris to Participate in the BofA Securities 2024 Health Care Conference
- May 2nd, 2024 9:00 pm
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
- May 2nd, 2024 2:01 pm
Viatris Expands Its Wellbeing Program With the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
- May 1st, 2024 10:30 pm
11 Best Low Price Pharma Stocks To Invest In
- Apr 21st, 2024 2:39 pm
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
- Apr 19th, 2024 10:00 am
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
- Apr 18th, 2024 3:12 pm
Bill Miller’s Latest 13 Stock Picks
- Apr 18th, 2024 1:54 pm
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
- Apr 16th, 2024 8:30 pm
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
- Apr 15th, 2024 12:00 pm
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
- Apr 15th, 2024 10:59 am
Competition watchdog says HRT drug deal could raise prices
- Apr 4th, 2024 11:50 am
UPDATE 1-UK watchdog says Theramex-Viatris deal raises competition concerns
- Apr 4th, 2024 10:52 am
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
- Apr 1st, 2024 6:01 pm
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
- Apr 1st, 2024 3:52 pm
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
- Apr 1st, 2024 11:14 am
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
- Apr 1st, 2024 10:59 am
Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?
- Mar 29th, 2024 3:30 pm
Scroll